Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxart

Full company profile

uuid0000qnr

Namestring
Vaxart
Legal namestring
Vaxart, Inc.
Websiteurl
vaxart.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which employs a non-replicating recombinant adenovirus Type 5 (rAd5) vector combined with protein antigens and a molecular adjuvant. The platform enables modular vaccine development and is designed to elicit both mucosal and systemic immunity through oral delivery to the small intestine, with thermostable formulations that eliminate cold-chain storage requirements. The clinical pipeline includes VXA-CoV2-3.3 (oral COVID-19 vaccine in Phase 2b funded by BARDA under Project NextGen, with an award up to $460 million), VXA-G1.1-NN (oral norovirus vaccine in Phase 1/2 development), an oral influenza vaccine that demonstrated 39% reduction in clinical disease versus 27% for Fluzone in a Phase 2 challenge study, and an HPV therapeutic vaccine in preclinical development.

The company's revenue model is anchored on non-dilutive government funding and strategic partnerships rather than commercial product sales. BARDA provides milestone-based funding under Project NextGen, with approximately $345 million currently available and total awards up to $460 million. An exclusive worldwide license and collaboration agreement with Dynavax Technologies (acquired by Sanofi in February 2026) for the oral COVID-19 vaccine generated $25 million upfront plus a $5 million equity investment, with potential milestones, royalties, and fees up to $700 million. Following Phase 2b data readout (expected late 2026), Dynavax/Sanofi may assume late-stage development and commercialization responsibilities. The company has supplemented these with equity financings including a $40 million underwritten offering (June 2024), a $10 million registered direct offering with RA Capital (January 2024), and a $25 million share purchase facility with Lincoln Park Capital Fund (April 2026). As of December 31, 2025, Vaxart reported $63.8 million in cash with runway into Q2 2027, supported by 101-250 employees (following a 21% workforce reduction in 2025) at its South San Francisco headquarters.

The company serves government health agencies (primary), healthcare providers, the general public (via future commercial products), and global health organizations (including the Gates Foundation, which funded norovirus research in lactating mothers). Vaxart is publicly traded under ticker VXRT on OTCMKTS (delisted from Nasdaq in November 2025) and faces governance friction including a proxy battle at its July 2026 Annual Meeting with dissident shareholders seeking to replace half the board.

Short descriptiontext

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary VAAST platform, with a Phase 2b COVID-19 program funded by BARDA and an exclusive worldwide license held by Dynavax (now part of Sanofi).

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral pill vaccines, recombinant vaccines, mucosal immunity platform, clinical-stage biotechnology, vaccine development
Industry5 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Oral Vaccines
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Government Contracts
TypeSubscription Recurring
Description

Vaxart receives substantial funding from BARDA under Project NextGen for its Phase 2b COVID-19 oral vaccine trial, with awards valued at up to $460 million. The company also received approximately $29 million in additional BARDA funding released in June 2026, bringing total available funding to approximately $345 million. Total BARDA project award is worth up to $453 million.

biospace.com
2Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Exclusive worldwide license and collaboration agreement with Dynavax Technologies for oral COVID-19 vaccine. Vaxart received $25 million upfront payment and $5 million equity investment, with potential milestone payments, royalties, and fees up to $700 million total.

investors.vaxart.com
3Equity Financing Facility
TypeTransaction Fee
Description

Share purchase agreement with Lincoln Park Capital Fund providing access to up to $25 million in common stock sales over a 24-month period at prevailing market prices, with no warrants or rights of first refusal.

in.investing.com
4Product Sales (Future)
TypeOne Time License
Description

Once vaccines receive regulatory approval, the company plans to commercialize oral pill vaccines for COVID-19, norovirus, influenza, and HPV through partnerships and direct sales to healthcare providers and government agencies.

in.investing.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines built on its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which combines a non-replicating recombinant adenovirus Type 5 (rAd5) delivery vector with viral protein antigens and a molecular adjuvant. The portfolio includes lead candidates targeting COVID-19 (VXA-CoV2-3.3), norovirus (VXA-G1.1-NN), influenza, and HPV, all designed for needle-free oral administration that elicits mucosal and systemic immunity without cold-chain requirements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 39% reduction in clinical disease for influenza vs 27% for Fluzone injectable vaccine
+5 more records
Product overview1 text field

Vaxart is a clinical-stage biotechnology company developing a portfolio of oral recombinant pill vaccines based on its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform. The platform combines recombinant adenovirus Type 5 (rAd5) as a non-replicating delivery vector with antigens and molecular adjuvants. The product portfolio includes: VXA-CoV2-3.3 (oral COVID-19 vaccine candidate in Phase 2b with BARDA funding), VXA-G1.1-NN (oral norovirus vaccine in Phase 1/2 development with Phase 3 planned), an oral influenza vaccine (completed Phase 2 challenge study), and an HPV therapeutic vaccine (preclinical stage). All vaccines are designed for oral pill administration, eliminating needles, cold-chain storage requirements, and injection site reactions while generating both mucosal and systemic immunity.

Product and service5 records
1VXA-CoV2-3.3 (Oral COVID-19 Vaccine)
CategoryCore Product
Description

An oral pill COVID-19 vaccine candidate built on the VAAST platform, designed to generate mucosal and systemic immunity at respiratory tract surfaces with potential broad protection across SARS-CoV-2 variants and no cold-chain requirements. Currently in Phase 2b clinical trial funded by BARDA under Project NextGen (award up to $460 million), licensed exclusively worldwide to Dynavax (now part of Sanofi).

2VXA-G1.1-NN (Oral Norovirus Vaccine)
CategoryCore Product
Description

A bivalent oral pill vaccine targeting the two norovirus genogroups most associated with human infections. Designed to produce mucosal antibodies locally in the intestine plus systemic antibodies. In Phase 1/2 development with Phase 3 planned; supported by the Bill & Melinda Gates Foundation for maternal immunization applications, with a Phase 1 study showing 4-6-fold increase in norovirus antibodies in breast milk from lactating mothers.

3Oral Influenza Vaccine
CategoryCore Product
Description

An oral pill influenza vaccine using the VAAST platform. Phase 2 human challenge study demonstrated comparable or superior efficacy to the market-leading Fluzone injectable vaccine, with 39% reduction in clinical disease and 47% reduction in infection rates. A Taiwan Biotech Forum presentation also noted a 49% relative reduction in influenza infection rates.

4HPV Therapeutic Vaccine
CategoryCore Product
Description

An oral pill therapeutic vaccine for HPV-related cervical dysplasia targeting HPV 16 and HPV 18 proteins responsible for transforming healthy cells. Preclinical studies demonstrate stimulation of T-cell immune responses, reduction in tumor size, and increased survival in animal models.

5VAAST Platform (Vector-Adjuvant-Antigen Standardized Technology)
CategoryPlatform
Description

Vaxart's proprietary modular vaccine platform combining recombinant adenovirus Type 5 (rAd5) as a non-replicating delivery vector, viral protein antigens, and a molecular adjuvant. Enables rapid insertion of protein antigens into the nucleic acid-based vector to create vaccines against existing and emerging pathogens, delivered as oral pills that stimulate both mucosal and systemic immunity.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-05
Description

Dynavax and Vaxart entered an exclusive worldwide license and collaboration agreement for Vaxart's oral COVID-19 vaccine candidate. Dynavax paid $25 million upfront and made a $5 million equity investment, with additional milestone payments contingent on development progress. Vaxart leads development through Phase 2b, after which Dynavax may assume late-stage development and commercialization. Sanofi acquired Dynavax in February 2026.

Strategic tierMinorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-01-01
Description

Vaxart originally licensed worldwide rights to develop and commercialize vapendavir to Altesa BioSciences in 2021 under an exclusive agreement worth up to $130 million in potential milestones and royalties. Altesa raised $75 million in Series B funding in February 2026 to advance the drug through Phase IIb trials for COPD patients.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Moderna is a leading mRNA vaccine company with an approved COVID-19 vaccine and pipeline across infectious diseases including influenza and norovirus. Both companies compete in developing next-generation vaccines against similar pathogens, though Moderna uses mRNA technology delivered by injection while Vaxart uses adenovirus vector delivered orally.

TypeDirect peer
Description

Novavax is a clinical-stage and commercial-stage vaccine developer with an approved protein subunit COVID-19 vaccine and pipeline including influenza candidates. Vaxart's CMO Dr. Cummings was previously VP Clinical Development at Novavax. Both companies compete in COVID-19 and influenza vaccine development with differentiated platform technologies.

TypeDirect peer
Description

Bavarian Nordic is a vaccine company with approved products including smallpox and Ebola vaccines, and is developing vaccines for respiratory syncytial virus and other infectious diseases. Vaxart Director Dr. Breitmeyer was President of Bavarian Nordic. Both companies focus on differentiated vaccine platforms targeting infectious diseases.

TypeDirect peer
Description

Dynavax (now part of Sanofi) developed the CpG 1018 adjuvant used in approved hepatitis B and COVID-19 vaccines. Dynavax is Vaxart's exclusive worldwide licensee for the oral COVID-19 vaccine candidate, making it both a direct partner and a comparable vaccine platform/adjuvant technology company.

TypeDirect peer
Description

CureVac is an mRNA vaccine company developing COVID-19, influenza, and rabies vaccines. As a clinical-stage vaccine developer focused on infectious diseases, CureVac is comparable in scale and stage to Vaxart, with both competing for government funding and partnership opportunities.

TypeEmerging player
Description

Arcturus is a clinical-stage mRNA vaccine and therapeutics company with COVID-19 vaccine approvals and pipeline programs in influenza and other infectious diseases. Comparable to Vaxart in clinical stage, scale, and platform-based approach to vaccine development against similar indications.

TypeEmerging player
Description

Icosavax is a clinical-stage biotechnology company developing VLP (virus-like particle) vaccines against infectious diseases including respiratory syncytial virus (RSV) and SARS-CoV-2. As a clinical-stage vaccine platform company developing next-generation technologies, Icosavax is comparable in size, stage, and strategic positioning to Vaxart.

TypeBroad incumbent
Description

Pfizer, together with BioNTech, developed and commercializes the leading mRNA COVID-19 vaccine (Comirnaty) and has an extensive infectious disease vaccine portfolio. As a broad incumbent in vaccines including COVID-19 and influenza, Pfizer competes against Vaxart for market share, government contracts, and partnership opportunities.

TypeBroad incumbent
Description

BioNTech partnered with Pfizer to develop and commercialize the leading mRNA COVID-19 vaccine and has an expanding pipeline across infectious diseases and oncology. As a platform-based vaccine developer using mRNA technology, BioNTech is comparable to Vaxart in modality focus but vastly larger in resources and commercial reach.

TypeDirect peer
Description

Altimmune is a clinical-stage biopharmaceutical company developing intranasal vaccines including an intranasal COVID-19 vaccine candidate and therapies for liver disease. Both Altimmune and Vaxart are clinical-stage companies pursuing non-injectable vaccine delivery methods (intranasal vs oral) targeting similar infectious disease indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds18 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxart

Oral Vaccinesvaxart.com

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary VAAST platform, with a Phase 2b COVID-19 program funded by BARDA and an exclusive worldwide license held by Dynavax (now part of Sanofi).

What Vaxart does

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which employs a non-replicating recombinant adenovirus Type 5 (rAd5) vector combined with protein antigens and a molecular adjuvant. The platform enables modular vaccine development and is designed to elicit both mucosal and systemic immunity through oral delivery to the small intestine, with thermostable formulations that eliminate cold-chain storage requirements. The clinical pipeline includes VXA-CoV2-3.3 (oral COVID-19 vaccine in Phase 2b funded by BARDA under Project NextGen, with an award up to $460 million), VXA-G1.1-NN (oral norovirus vaccine in Phase 1/2 development), an oral influenza vaccine that demonstrated 39% reduction in clinical disease versus 27% for Fluzone in a Phase 2 challenge study, and an HPV therapeutic vaccine in preclinical development.

The company's revenue model is anchored on non-dilutive government funding and strategic partnerships rather than commercial product sales. BARDA provides milestone-based funding under Project NextGen, with approximately $345 million currently available and total awards up to $460 million. An exclusive worldwide license and collaboration agreement with Dynavax Technologies (acquired by Sanofi in February 2026) for the oral COVID-19 vaccine generated $25 million upfront plus a $5 million equity investment, with potential milestones, royalties, and fees up to $700 million. Following Phase 2b data readout (expected late 2026), Dynavax/Sanofi may assume late-stage development and commercialization responsibilities. The company has supplemented these with equity financings including a $40 million underwritten offering (June 2024), a $10 million registered direct offering with RA Capital (January 2024), and a $25 million share purchase facility with Lincoln Park Capital Fund (April 2026). As of December 31, 2025, Vaxart reported $63.8 million in cash with runway into Q2 2027, supported by 101-250 employees (following a 21% workforce reduction in 2025) at its South San Francisco headquarters.

The company serves government health agencies (primary), healthcare providers, the general public (via future commercial products), and global health organizations (including the Gates Foundation, which funded norovirus research in lactating mothers). Vaxart is publicly traded under ticker VXRT on OTCMKTS (delisted from Nasdaq in November 2025) and faces governance friction including a proxy battle at its July 2026 Annual Meeting with dissident shareholders seeking to replace half the board.

Vaxart firmographics

Firmographics
Name
Vaxart
Legal name
Vaxart, Inc.
Website
https://vaxart.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
101–250 employees
Short description
Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines using its proprietary VAAST platform, with a Phase 2b COVID-19 program funded by BARDA and an exclusive worldwide license held by Dynavax (now part of Sanofi).
Ownership category
akta.pro rank

Vaxart industry classification

Industry
Product category
Oral Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAIAEAI
Vaccine Adjuvants & Formulation Systems
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Oral pill vaccines
  • Recombinant vaccines
  • Mucosal immunity platform
  • Clinical-stage biotechnology
  • Vaccine development

Where Vaxart is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Vaxart business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Government Contracts: Vaxart receives substantial funding from BARDA under Project NextGen for its Phase 2b COVID-19 oral vaccine trial, with awards valued at up to $460 million. The company also received approximately $29 million in additional BARDA funding released in June 2026, bringing total available funding to approximately $345 million. Total BARDA project award is worth up to $453 million.
  2. Licensing and Partnership Revenue: Exclusive worldwide license and collaboration agreement with Dynavax Technologies for oral COVID-19 vaccine. Vaxart received $25 million upfront payment and $5 million equity investment, with potential milestone payments, royalties, and fees up to $700 million total.
  3. Equity Financing Facility: Share purchase agreement with Lincoln Park Capital Fund providing access to up to $25 million in common stock sales over a 24-month period at prevailing market prices, with no warrants or rights of first refusal.
  4. Product Sales (Future): Once vaccines receive regulatory approval, the company plans to commercialize oral pill vaccines for COVID-19, norovirus, influenza, and HPV through partnerships and direct sales to healthcare providers and government agencies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Vaxart product offering

Product offering

Core offering

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines built on its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which combines a non-replicating recombinant adenovirus Type 5 (rAd5) delivery vector with viral protein antigens and a molecular adjuvant. The portfolio includes lead candidates targeting COVID-19 (VXA-CoV2-3.3), norovirus (VXA-G1.1-NN), influenza, and HPV, all designed for needle-free oral administration that elicits mucosal and systemic immunity without cold-chain requirements.

Product overview

Vaxart is a clinical-stage biotechnology company developing a portfolio of oral recombinant pill vaccines based on its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform. The platform combines recombinant adenovirus Type 5 (rAd5) as a non-replicating delivery vector with antigens and molecular adjuvants. The product portfolio includes: VXA-CoV2-3.3 (oral COVID-19 vaccine candidate in Phase 2b with BARDA funding), VXA-G1.1-NN (oral norovirus vaccine in Phase 1/2 development with Phase 3 planned), an oral influenza vaccine (completed Phase 2 challenge study), and an HPV therapeutic vaccine (preclinical stage). All vaccines are designed for oral pill administration, eliminating needles, cold-chain storage requirements, and injection site reactions while generating both mucosal and systemic immunity.

Differentiator

Problem solved

Functional benefit

Products and services

  • VXA-CoV2-3.3 (Oral COVID-19 Vaccine) An oral pill COVID-19 vaccine candidate built on the VAAST platform, designed to generate mucosal and systemic immunity at respiratory tract surfaces with potential broad protection across SARS-CoV-2 variants and no cold-chain requirements. Currently in Phase 2b clinical trial funded by BARDA under Project NextGen (award up to $460 million), licensed exclusively worldwide to Dynavax (now part of Sanofi).
  • VXA-G1.1-NN (Oral Norovirus Vaccine) A bivalent oral pill vaccine targeting the two norovirus genogroups most associated with human infections. Designed to produce mucosal antibodies locally in the intestine plus systemic antibodies. In Phase 1/2 development with Phase 3 planned; supported by the Bill & Melinda Gates Foundation for maternal immunization applications, with a Phase 1 study showing 4-6-fold increase in norovirus antibodies in breast milk from lactating mothers.
  • Oral Influenza Vaccine An oral pill influenza vaccine using the VAAST platform. Phase 2 human challenge study demonstrated comparable or superior efficacy to the market-leading Fluzone injectable vaccine, with 39% reduction in clinical disease and 47% reduction in infection rates. A Taiwan Biotech Forum presentation also noted a 49% relative reduction in influenza infection rates.
  • HPV Therapeutic Vaccine An oral pill therapeutic vaccine for HPV-related cervical dysplasia targeting HPV 16 and HPV 18 proteins responsible for transforming healthy cells. Preclinical studies demonstrate stimulation of T-cell immune responses, reduction in tumor size, and increased survival in animal models.
  • VAAST Platform (Vector-Adjuvant-Antigen Standardized Technology) Vaxart's proprietary modular vaccine platform combining recombinant adenovirus Type 5 (rAd5) as a non-replicating delivery vector, viral protein antigens, and a molecular adjuvant. Enables rapid insertion of protein antigens into the nucleic acid-based vector to create vaccines against existing and emerging pathogens, delivered as oral pills that stimulate both mucosal and systemic immunity.

Quantifiable outcome

  • 39% reduction in clinical disease for influenza vs 27% for Fluzone injectable vaccine
  • +5 more outcomes

Companies that use Vaxart

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Vaxart technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Vaxart partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and minor.

  • Dynavax Technologies (now Sanofi)flagshipStrategic or Co-development Partner · 5 November 2025Dynavax and Vaxart entered an exclusive worldwide license and collaboration agreement for Vaxart's oral COVID-19 vaccine candidate. Dynavax paid $25 million upfront and made a $5 million equity investment, with additional milestone payments contingent on development progress. Vaxart leads development through Phase 2b, after which Dynavax may assume late-stage development and commercialization. Sanofi acquired Dynavax in February 2026.
  • Altesa BioSciencesminorOEM/ Whitelabel/ Licensing Partner · 1 January 2021Vaxart originally licensed worldwide rights to develop and commercialize vapendavir to Altesa BioSciences in 2021 under an exclusive agreement worth up to $130 million in potential milestones and royalties. Altesa raised $75 million in Series B funding in February 2026 to advance the drug through Phase IIb trials for COPD patients.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Vaxart competitors and assessment

Company assessment

Broad incumbents

  • Moderna: Moderna is a leading mRNA vaccine company with an approved COVID-19 vaccine and pipeline across infectious diseases including influenza and norovirus. Both companies compete in developing next-generation vaccines against similar pathogens, though Moderna uses mRNA technology delivered by injection while Vaxart uses adenovirus vector delivered orally.
  • Pfizer: Pfizer, together with BioNTech, developed and commercializes the leading mRNA COVID-19 vaccine (Comirnaty) and has an extensive infectious disease vaccine portfolio. As a broad incumbent in vaccines including COVID-19 and influenza, Pfizer competes against Vaxart for market share, government contracts, and partnership opportunities.
  • BioNTech: BioNTech partnered with Pfizer to develop and commercialize the leading mRNA COVID-19 vaccine and has an expanding pipeline across infectious diseases and oncology. As a platform-based vaccine developer using mRNA technology, BioNTech is comparable to Vaxart in modality focus but vastly larger in resources and commercial reach.

Direct peers

  • Novavax: Novavax is a clinical-stage and commercial-stage vaccine developer with an approved protein subunit COVID-19 vaccine and pipeline including influenza candidates. Vaxart's CMO Dr. Cummings was previously VP Clinical Development at Novavax. Both companies compete in COVID-19 and influenza vaccine development with differentiated platform technologies.
  • Bavarian Nordic: Bavarian Nordic is a vaccine company with approved products including smallpox and Ebola vaccines, and is developing vaccines for respiratory syncytial virus and other infectious diseases. Vaxart Director Dr. Breitmeyer was President of Bavarian Nordic. Both companies focus on differentiated vaccine platforms targeting infectious diseases.
  • Dynavax Technologies: Dynavax (now part of Sanofi) developed the CpG 1018 adjuvant used in approved hepatitis B and COVID-19 vaccines. Dynavax is Vaxart's exclusive worldwide licensee for the oral COVID-19 vaccine candidate, making it both a direct partner and a comparable vaccine platform/adjuvant technology company.
  • CureVac: CureVac is an mRNA vaccine company developing COVID-19, influenza, and rabies vaccines. As a clinical-stage vaccine developer focused on infectious diseases, CureVac is comparable in scale and stage to Vaxart, with both competing for government funding and partnership opportunities.
  • Altimmune: Altimmune is a clinical-stage biopharmaceutical company developing intranasal vaccines including an intranasal COVID-19 vaccine candidate and therapies for liver disease. Both Altimmune and Vaxart are clinical-stage companies pursuing non-injectable vaccine delivery methods (intranasal vs oral) targeting similar infectious disease indications.

Emerging players

  • Arcturus Therapeutics: Arcturus is a clinical-stage mRNA vaccine and therapeutics company with COVID-19 vaccine approvals and pipeline programs in influenza and other infectious diseases. Comparable to Vaxart in clinical stage, scale, and platform-based approach to vaccine development against similar indications.
  • Icosavax: Icosavax is a clinical-stage biotechnology company developing VLP (virus-like particle) vaccines against infectious diseases including respiratory syncytial virus (RSV) and SARS-CoV-2. As a clinical-stage vaccine platform company developing next-generation technologies, Icosavax is comparable in size, stage, and strategic positioning to Vaxart.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Vaxart social profiles

Digital presence

Vaxart financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxart leadership team

Management profile

Number of profiles

Profiles8 records

Vaxart funding detail

Funding detail

Funding overview

Funding rounds18 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxart M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxart

What does Vaxart do?

Vaxart is a clinical-stage biotechnology company developing oral recombinant pill vaccines built on its proprietary VAAST (Vector-Adjuvant-Antigen Standardized Technology) platform, which combines a non-replicating recombinant adenovirus Type 5 (rAd5) delivery vector with viral protein antigens and a molecular adjuvant. The portfolio includes lead candidates targeting COVID-19 (VXA-CoV2-3.3), norovirus (VXA-G1.1-NN), influenza, and HPV, all designed for needle-free oral administration that elicits mucosal and systemic immunity without cold-chain requirements.

Is Vaxart a public or private company?

Vaxart is a public company. It is classified as public and is currently operating.

When was Vaxart founded?

Vaxart was founded in 2008. It employs 101 to 250 people.

Where is Vaxart based?

Vaxart is headquartered in South San Francisco, United States, in the North America region.

How does Vaxart make money?

Four revenue lines are on record. Government Contracts are the primary driver. The others are licensing and Partnership Revenue, equity Financing Facility and product Sales (Future).

Who are Vaxart's main competitors?

Broad incumbents on record are Moderna, Pfizer and BioNTech. Direct peers are Novavax, Bavarian Nordic, Dynavax Technologies, CureVac and Altimmune. Emerging players are Arcturus Therapeutics and Icosavax.

Does Vaxart have an API?

No public API is recorded for Vaxart.

What industry is Vaxart in?

Vaxart's product category is Oral Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewVaxart Q3 2026 Earnings Call Is LiveVaxart's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. Management commentary on future demand, margins, or capital spending may move markets.MarketBeatVaxart (VXRT) Projected to Announce Quarterly Earnings on ThursdayVaxart is projected to report Q3 2026 earnings after market close on November 5th, with analysts expecting a loss of $0.03 per share and revenue of $27.20 million. The company's last quarterly results showed a loss of $0.06 per share and revenue of $27.18 million. Analysts have a consensus 'Hold' rating with a price target of $0.43.American Banking and Market NewsVaxart (VXRT) Projected to Release Earnings on ThursdayVaxart is expected to report Q3 2026 earnings after market close on Thursday, November 5th, with analysts projecting a loss of $0.03 per share and revenue of $27.20 million. The company's last quarterly report showed a loss of $0.06 per share and revenue of $27.18 million. A conference call is scheduled for Friday, November 6th.Ticker ReportHypermarcas (OTCMKTS:HYPMY) & Vaxart (OTCMKTS:VXRT) Head to Head SurveyHypermarcas beats Vaxart on 8 of 13 factors, including higher revenue ($1.38B vs $237.26M) and earnings ($213.10M vs $16.33M). Vaxart trades at a lower P/E ratio, while Hypermarcas has lower volatility. Analyst ratings favor Hypermarcas with a 3.00 score versus Vaxart's 2.00.Ticker ReportVaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright ConferenceVaxart CEO Steve Lo presented its oral vaccine platform and COVID-19 trial progress at an H.C. Wainwright conference. The company has dosed 3,880 subjects and fully enrolled 5,400 in its BARDA-funded Phase IIb COVID-19 trial, with a 12-month efficacy readout expected in early 2027. It also highlighted norovirus and influenza candidates, seeking partnerships to advance them.BioSpaceVaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine TechnologyVaxart announced the European Patent Office granted a new patent (No. 3791859) for its oral recombinant norovirus vaccine, extending IP protection through at least 2036 across 13 European jurisdictions. The patent covers its room-temperature stable, needle-free pill delivery platform, which the company says secures an advantage over injected norovirus candidates.Stock TitanVaxart Gets European Patent, Norovirus IP to at Least 2036Vaxart announced on August 26, 2026 that the European Patent Office formally published the grant of European Patent No. 3791859, protecting its oral recombinant norovirus vaccine candidate. The patent extends IP protection through at least 2036 across 13 European jurisdictions, including Germany, France, Italy, Spain and the UK. The patent will be validated in additional territories, including Austria, Belgium, Denmark, Ireland, the Netherlands, Norway, Sweden and Switzerland.Ticker ReportVaxart (OTCMKTS:VXRT) Stock Passes Below 200-Day Moving Average – Here’s WhyVaxart shares dropped below their 200-day moving average of $0.62, trading as low as $0.4705 on Monday with a last price of $0.4940. Zacks Research recently upgraded the stock to a "hold" rating, while institutional investors including Raymond James and Invesco increased their positions in the company during recent quarters.AInvestVXRT: The Q2 Revenue Decline Is Accounting Noise — the $675 Million Optionality Is What the Market Is IgnoringVaxart reported Q2 revenue of $27.2 million, a 31% decline year-over-year, driven by the winding down of BARDA contract billing milestones rather than business deterioration. The company holds $675 million in contingent milestones from Dynavax Technologies and a separate $700 million milestone path with Sanofi tied to its oral COVID-19 vaccine program, while currently trading at a $130 million market cap. The Phase 2b efficacy readout expected in the first half of 2027 represents a binary catalyst that the market is currently not pricing in, with clean safety data from a 400-person sentinel cohort already reported in July 2026.Seeking AlphaVaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)Vaxart, Inc. announced its Phase IIb COVID-19 vaccine top line data in the first half of 2027, supported by funding from BARDA, as part of its ongoing development progress. The company reported a pivotal period of execution and milestones achieved in Q2 2026.